[1] Cheson BD. Radioimmunotheraphy of non-Hodgkin lymphomas.Blood, 2003, 101(2):391-398.
[2] DeNardo GL. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs). Semin Nucl Med, 2005, 35(3):202-211.
[3] Kaminski MS, Tuck M, Estes J, et al. 131Ⅰ-tositumomab therapy asinitial treatment for follicular lymphoma. N Engl J Med, 2005,352(5):441-449.
[4] Dadachova E, Bryan RA, Apostolidis C, et al. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. Infect Dis, 2006, 193(10):1427-1436.
[5] Buchsbaum DJ. Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs. Semin Nucl Med, 2004, 34(1):32-46.
[6] Garambois V, Glaussel F, Foulquier E, et al. Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA)Gold 4 epitope and designed for radioimmunotherapy(RIT) of colorectalcancers. BMC Cancer, 2004, 75(4):1471-1482.
[7] Chen ZN, Mi L, Xu J, et al. Targeting radioimmunotherapy of hepat-ocell carcinoma with iodine (131Ⅰ) metuximab injection:clinical phase Ⅰ/Ⅱ trials. Int J Radiat Oncol Biol Phys, 2006, 65(2):435-444.
[8] Garkavij M, Samarzija M, Ewers SB, et al. Concurrent radiotherapy and tumor targeting with 131Ⅰn-HMFG1-F(ab')2 in patients with MUC1-positive non-small cell lung cancer. Anticancer Res, 2005, 25(6C):4663-4667.
[9] Li G, Wang Y, Huang K, et al. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. Nucl Med Biol, 2005, 32(1):59-65.
[10] Morandeau L, Benoist E, Loussouarn A, et al. Synthesis of new bivalent peptides for applications in the affinity enhancement system. Bioconjug Chem, 2005, 16(1):184-193.
[11] Boerman OC, Oyen WJG, Corstens FHM. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney. Eur J Nucl Med, 2001, 28(10):1552-1554.
[12] Bodei L, Hauekiewicz-Junak D, Grana C, et aL Receptor radionuclide theraphy with Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiophasm, 2004, 19(1):65-71.
[13] Schmitt A, Bernhardt P, Nilsson O, et al. Radiation therapy of small cell lung cancer with 117Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med, 2004, 45(9):1542-1548.